MedTrace Logo

Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer

NCT00156273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2017-07-05

No results posted yet for this study

Summary

We are trying to develop better ways to detect when cancer therapies are working.

Conditions

Sponsors & Collaborators

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Jeffrey Smerage, M.D., Ph.D. · University of Michigan Rogel Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156273 on ClinicalTrials.gov